celecoxib has been researched along with Prostatic Neoplasms, Castration-Resistant in 3 studies
Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benelli, R | 1 |
| Barboro, P | 1 |
| Costa, D | 1 |
| Astigiano, S | 1 |
| Barbieri, O | 1 |
| Capaia, M | 1 |
| Poggi, A | 1 |
| Ferrari, N | 1 |
| Kattan, J | 1 |
| Bachour, M | 1 |
| Farhat, F | 1 |
| El Rassy, E | 1 |
| Assi, T | 1 |
| Ghosn, M | 1 |
| Jeong, Y | 1 |
| Lee, JL | 1 |
1 trial available for celecoxib and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 2016 |
2 other studies available for celecoxib and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.
Topics: Amphiregulin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Li | 2019 |
Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclophosphamide | 2017 |